Objective To analyze the curative effect and safety of Chinese patent medicine combining Western drugs on hypertensive left ventricular hypertrophy (LVH). Methods The databases of PubMed, EMbase, Cochrone Library, CNKI, WangFang Database and VIP Database were retrieved with computers for collecting randomized controlled trials (RCT) about the curative effect of Chinese patent medicine combining Western drugs on LVH up to Oct. 2013. A Meta-analysis was conducted by using RevMan5.2 software. Results There were totally 14 RCT included involving 1055 patients. The results of Meta-analysis showed that①Chinese patent medicine combining Western drugs had better effect than only Western drugs, and the comparison in LVDd [WMD=-1.38, 95%CI (-2.36--0.71), P<0.0001], IVST [WMD=-1.08, 95%CI (-1.67--0.49), P=0.0002], LVPWT [WMD=-0.99, 95%CI (-1.54- -0.45), P=0.000 3], and LVMI [WMD=-8.55, 95%CI (-11.67- -5.43), P<0.00001] showed statistical significance between two groups. ②The comparison in SBP [WMD=-5.31, 95%CI (-11.23- 0.60), P=0.08] had no significant difference, in DBP [WMD=-3.42, 95%CI (-5.53--1.31), P=0.001]) had significant difference, and in antihypertensive efficiency [OR=1.68, 95%CI (0.59-4.74), P=0.33] had no significant difference between two groups. ③The comparison in relief of clinical symptoms [OR=5.74, 95%CI (2.70-12.21), P<0.00001] had statistical significance between two groups. Conclusion Chinese patent medicine combining Western drugs has better effect in adversing LVH, reduces significantly DPB and relieves clinical symptoms compared with only Western drugs. However, more with multiple-center, large-sample and adequate randomized RCT, and allocation concealment, blinding design and long-term follow-up are required.